ADA and rheumatoid arthritis: Finally, IPA of RA patients receiving ADA/IFX and those receiving no TNFi confirmed, according to the top diseases and functions, a decrease in rheumatic disease (activation score −2.2, 89 molecules related) and inflammation of joints (activation score −2.3, 69 molecules related) (Supplementary Figure 2B).